Emglizin Met

Emglizin Met

An oral hypoglycemic agent is an inhibitor of sodium-dependent glucose transporter type 2.


  • Empagliflozin MS 12.5 mg
  • Metformin hydrochloride USP 850 mg.

Emglizin Met is indicated for the treatment of type 2 diabetes mellitus in adult patients as an adjunct to diet therapy and exercise to improve glycemic control:

  • with unsatisfactory glycemic control during monotherapy with metformin at the maximum tolerated dose;
  • in combination with other hypoglycemic drugs with unsatisfactory glycemic control due to their combined use with metformin;
  • in patients who have previously received combination therapy with empagliflozin and metformin in the form of separate drugs.

Adult patients with normal renal function (GFR ≥ 90 ml/min).

General recommendation:

  • 1 tablet 2 times a day, take with meals.

Individual correction:

  • The dosage may be adjusted depending on the current therapy, its effectiveness and tolerability.

Maximum dose:

  • No more than 25 mg of empagliflozin and 2000 mg of metformin per day.

Change of therapy:

  • If the patient has previously taken empagliflozin or metformin alone, the dose of Emglizin Met should be consistent with previous doses.

Combination with other drugs:

  • When combined with sulfonylureas or insulin, their doses may be adjusted to reduce the risk of hypoglycemia.

Kidney failure:

  • Patients with mild renal impairment do not require dose adjustment, but require regular monitoring of renal function.